[Temozolomide for anaplastic oligodendroglioma]
Pichon Riviere A, Augustovski F, Garcia Marti S, Alcaraz A, Glujovsky D, Lopez A, Rey-Ares L, Bardach A, Ciapponi A, Brito B
Record ID 32014000244
Spanish
Authors' objectives:
To assess the available evidence on the efficacy, safety and coverage related issues regarding to the use of temozolomide in patients with anaplastic oligodendroglioma.
Authors' recommendations:
There is poor quality evidence assessing TMZ for de novo or recurrent AO treatment. It includes only one RCT and several case series in heterogeneous populations with malignant gliomas, among which AO in different clinical conditions is included. In general, the studies do not clearly allow determining the superiority of TMZ over strategies considered as first line such as radiotherapy or PCV. However, the clinical practice guidelines consider TMZ alone or in combination with radiotherapy as a therapeutic option for de novo AO, and as an appropriate alternative among initial treatments in recurrent AO.
Details
Project Status:
Completed
Year Published:
2013
URL for published report:
https://www.iecs.org.ar/home-ets/?cod_publicacion=1563&familia=5&origen_publicacion=buscador
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Dacarbazine
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.